This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 265.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Matinas Biopharma Holdings, Inc. (MTNB)
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 87.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines
by Zacks Equity Research
Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.
Matinas Biopharma Holdings, Inc. (MTNB) Loses 29.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Matinas Biopharma Holdings, Inc. (MTNB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Matinas Biopharma Holdings, Inc. (MTNB) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -67.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Matinas BioPharma (MTNB) Looks Good: Stock Adds 8.6% in Session
by Zacks Equity Research
Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Matinas Biopharma Holdings, Inc. (MTNB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Matinas BioPharma (MTNB) in Focus: Stock Moves 6% Higher
by Zacks Equity Research
Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Will Matinas BioPharma Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Matinas BioPharma
Matinas Biopharma Holdings Inc (MTNB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings Inc (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Prospects Appear Bright for Small Drug Industry in 2020
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity keep small drugmakers afloat in a competitive market.
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 25.00% and 50.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Matinas Biopharma Holdings, Inc. (MTNB) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.